Abstract Supplementary Table S1 Continuous Glucose Monitoring (CGM) has been
demonstrated to be clinically valuable, reducing risks of hypoglycemia and hyperglycemia …

The artificial pancreas (closed-loop system) addresses the unmet clinical need for improved
glucose control whilst reducing the burden of diabetes self-care in type 1 diabetes. Glucose …

Background: The safety and effectiveness of the in-home use of a hybrid closed-loop (HCL)
system that automatically increases, decreases, and suspends insulin delivery in response …

Methods| Patients aged 14 to 75 years with type 1 diabetes for at least 2 years, glycated
hemoglobin (HbA1c) less than 10%, and more than 6 months of insulin pump use were …

Objective To describe predictors of hybrid closed loop (HCL) discontinuation and perceived
barriers to use in youth with type 1 diabetes. Subjects Youth with type 1 diabetes (eligible …

Objective To describe glycemic and psychosocial outcomes in youth with type 1 diabetes
using a hybrid closed loop (HCL) system. Subjects Youth with type 1 diabetes (2‐25 years) …

OBJECTIVE The MiniMed 670G System is the first commercial hybrid closed-loop (HCL)
system for management of type 1 diabetes. Using data from adolescent and young adult …

Aim To evaluate the real‐world performance of the MiniMed 670G system in Europe, in
individuals with diabetes. Materials and Methods Data uploaded from October 2018 to July …

Recent, rapid changes in the treatment of type 1 diabetes have allowed for
commercialization of an “artificial pancreas” that is better described as a closed-loop …

Objective: The development of artificial pancreas (AP) technology for deployment in low-
energy, embedded devices is contingent upon selecting an efficient control algorithm for …